GRIT

GRIT Biotechnology is a China-based clinical-stage biopharmaceutical company focused on next-generation immune cell therapies, particularly tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Its lead program, GT101, is an autologous TIL therapy that has entered pivotal Phase 2 development in China for recurrent and metastatic cervical cancer. The company is also advancing gene-edited and armored TIL programs such as GT201 and GT300/GT307, and has expanded into adjacent platforms including neoantigen mRNA vaccines, in vivo CAR-T, and stem cell-derived allogeneic cell therapies. GRIT positions itself as a platform-driven immunotherapy company with integrated target discovery, gene-editing, cell engineering, and manufacturing capabilities. The company operates in China and the United States and has built internal GMP manufacturing capacity to support clinical development.